Literature DB >> 26353077

Gene expression profile in newborn rat lungs after two days of recovery of mechanical ventilation.

Valérie Dénervaud1, Sandrine Gremlich1, Eliane Trummer-Menzi1, Johannes C Schittny2, Matthias Roth-Kleiner1.   

Abstract

BACKGROUND: Preterm infants having immature lungs often require respiratory support, potentially leading to bronchopulmonary dysplasia (BPD). Conventional BPD rodent models based on mechanical ventilation (MV) present outcome measured at the end of the ventilation period. A reversible intubation and ventilation model in newborn rats recently allowed discovering that different sets of genes modified their expression related to time after MV. In a newborn rat model, the expression profile 48 h after MV was analyzed with gene arrays to detect potentially interesting candidates with an impact on BPD development.
METHODS: Rat pups were injected P4-5 with 2 mg/kg lipopolysaccharide (LPS). One day later, MV with 21 or 60% oxygen was applied during 6 h. Animals were sacrified 48 h after end of ventilation. Affymetrix gene arrays assessed the total gene expression profile in lung tissue.
RESULTS: In fully treated animals (LPS + MV + 60% O(2)) vs. controls, 271 genes changed expression significantly. All modified genes could be classified in six pathways: tissue remodeling/wound repair, immune system and inflammatory response, hematopoiesis, vasodilatation, and oxidative stress. Major alterations were found in the MMP and complement system.
CONCLUSION: MMPs and complement factors play a central role in several of the pathways identified and may represent interesting targets for BPD treatment/prevention.Bronchopulmonary dysplasia (BPD) is a chronic lung disease occurring in ~30% of preterm infants born less than 30 wk of gestation (1). Its main risk factors include lung immaturity due to preterm delivery, mechanical ventilation (MV), oxygen toxicity, chorioamnionitis, and sepsis. The main feature is an arrest of alveolar and capillary formation (2). Models trying to decipher genes involved in the pathophysiology of BPD are mainly based on MV and oxygen application to young mammals with immature lungs of different species (3). In newborn rodent models, analyses of lung structure and gene and protein expression are performed for practical reasons directly at the end of MV (4,5,6). However, later appearing changes of gene expression might also have an impact on lung development and the evolution towards BPD and cannot be discovered by such models. Recently, we developed a newborn rat model of MV using an atraumatic (orotracheal) intubation technique that allows the weaning of the newborn animal off anesthesia and MV, the extubation to spontaneous breathing, and therefore allows the evaluation of effects of MV after a ventilation-free period of recovery (7). Indeed, applying this concept of atraumatic intubation by direct laryngoscopy, we recently were able to show significant differences between gene expression changes appearing directly after MV compared to those measured after a ventilation-free interval of 48 h. Immediately after MV, inflammation-related genes showed a transitory modified expression, while another set of more structurally related genes changed their expression only after a delay of 2 d (7). Lung structure, analyzed by conventional 2D histology and also by 3D reconstruction using synchrotron x-ray tomographic microscopy revealed, 48 h after end of MV, a reduced complexity of lung architecture compared to the nonventilated rat lungs, similar to the typical findings in BPD. To extend these observations about late gene expression modifications, we performed with a similar model a full gene expression profile of lung tissue 48 h after the end of MV with either room air or 60% oxygen. Essentially, we measured changes in the expression of genes related to the MMPs and complement system which played a role in many of the six identified mostly affected pathways.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26353077     DOI: 10.1038/pr.2015.155

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  36 in total

1.  Up-regulation of trypsin and mesenchymal MMP-8 during development of hyperoxic lung injury in the rat.

Authors:  Katariina Cederqvist; Joakim Janer; Taina Tervahartiala; Timo Sorsa; Caj Haglund; Kaisa Salmenkivi; Ulf-Håkan Stenman; Sture Andersson
Journal:  Pediatr Res       Date:  2006-08-28       Impact factor: 3.756

Review 2.  Matrix metalloproteinases and the regulation of tissue remodelling.

Authors:  Andrea Page-McCaw; Andrew J Ewald; Zena Werb
Journal:  Nat Rev Mol Cell Biol       Date:  2007-03       Impact factor: 94.444

Review 3.  Metalloproteinases and their natural inhibitors in inflammation and immunity.

Authors:  Rama Khokha; Aditya Murthy; Ashley Weiss
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

Review 4.  Control mechanisms of lung alveolar development and their disorders in bronchopulmonary dysplasia.

Authors:  Jacques Bourbon; Olivier Boucherat; Bernadette Chailley-Heu; Christophe Delacourt
Journal:  Pediatr Res       Date:  2005-04-06       Impact factor: 3.756

5.  Inflammatory response to oxygen and endotoxin in newborn rat lung ventilated with low tidal volume.

Authors:  Andreas A Kroon; Jinxia Wang; Zhen Huang; Lei Cao; Maciej Kuliszewski; Martin Post
Journal:  Pediatr Res       Date:  2010-07       Impact factor: 3.756

6.  Absence or inhibition of matrix metalloproteinase-8 decreases ventilator-induced lung injury.

Authors:  Guillermo M Albaiceta; Ana Gutierrez-Fernández; Emilio García-Prieto; Xose S Puente; Diego Parra; Aurora Astudillo; Cristina Campestre; Sandra Cabrera; Adrian Gonzalez-Lopez; Antonio Fueyo; Francisco Taboada; Carlos López-Otin
Journal:  Am J Respir Cell Mol Biol       Date:  2009-12-07       Impact factor: 6.914

7.  Neonatal mice genetically modified to express the elastase inhibitor elafin are protected against the adverse effects of mechanical ventilation on lung growth.

Authors:  Anne Hilgendorff; Kakoli Parai; Robert Ertsey; G Juliana Rey-Parra; Bernard Thébaud; Rasa Tamosiuniene; Noopur Jain; Edwin F Navarro; Barry C Starcher; Mark R Nicolls; Marlene Rabinovitch; Richard D Bland
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-06-08       Impact factor: 5.464

8.  A role for matrix metalloproteinase 9 in IFNγ-mediated injury in developing lungs: relevance to bronchopulmonary dysplasia.

Authors:  Anantha Harijith; Rayman Choo-Wing; Sule Cataltepe; Ryuji Yasumatsu; Zubair H Aghai; Joakim Janér; Sture Andersson; Robert J Homer; Vineet Bhandari
Journal:  Am J Respir Cell Mol Biol       Date:  2011-01-07       Impact factor: 6.914

9.  The role of matrix metalloproteinases -9 and -2 in development of neonatal chronic lung disease.

Authors:  D G Sweet; A E Curley; E Chesshyre; J Pizzotti; M S Wilbourn; H L Halliday; J A Warner
Journal:  Acta Paediatr       Date:  2004-06       Impact factor: 2.299

10.  Low levels of tissue inhibitors of metalloproteinases with a high matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio are present in tracheal aspirate fluids of infants who develop chronic lung disease.

Authors:  Ikechukwu I Ekekezie; Donald W Thibeault; Stephen D Simon; Michael Norberg; Jeffrey D Merrill; Roberta A Ballard; Philip L Ballard; William E Truog
Journal:  Pediatrics       Date:  2004-06       Impact factor: 7.124

View more
  2 in total

1.  Urine Proteomics for Noninvasive Monitoring of Biomarkers in Bronchopulmonary Dysplasia.

Authors:  Saima Ahmed; Oludare A Odumade; Patrick van Zalm; Kinga K Smolen; Kimino Fujimura; Jan Muntel; Melissa S Rotunno; Abigail B Winston; Judith A Steen; Richard B Parad; Linda J Van Marter; Stella Kourembanas; Hanno Steen
Journal:  Neonatology       Date:  2022-01-24       Impact factor: 4.035

2.  Role of the LRP1-pPyk2-MMP9 pathway in hyperoxia-induced lung injury in neonatal rats.

Authors:  Ya-Fei Zheng; Hai-Yan Zhu; Wei Wang; Jing-Jing Hu; Tian-Ping Bao; Zhao-Fang Tian
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2021-12-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.